ScholarIQanswers from OpenAlex & ORCID
PierFranco Conte
ResearcherPublications, citations & collaboration network
PierFranco Conte is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does PierFranco Conte have?
ScholarIQindexed works
PierFranco Conte has 1,237 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does PierFranco Conte have?
ScholarIQcitation count
PierFranco Conte has 44,005 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of PierFranco Conte?
ScholarIQh-index
PierFranco Conte has an h-index of 94 in OpenAlex.
What is the i10-index of PierFranco Conte?
ScholarIQi10-index
PierFranco Conte has an i10-index of 438 in OpenAlex.
What is the ORCID of PierFranco Conte?
ScholarIQorcid
The ORCID for PierFranco Conte is on the source record.
What is the OpenAlex record for PierFranco Conte?
ScholarIQopenalex
The OpenAlex for PierFranco Conte is on the source record.
What are the most-cited papers on PierFranco Conte?
ScholarIQmost cited works
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Katarína Petráková, Kim T. Blackwell, Eric P. Winer, W Janni, S. Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Faye Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Maria Vittoria Dieci, Carmen Criscitiello, Aïcha Goubar, Giuseppe Viale, PierFranco Conte, Valentina Guarneri, Guido Ficarra, M.‐C. Mathieu, Suzette Delaloge, Giuseppe Curigliano, Fabrice André
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
Maria Vittoria Dieci, M.‐C. Mathieu, Valentina Guarneri, PierFranco Conte, Suzette Delaloge, Fabrice André, Aïcha Goubar